On a collaboration streak, Merck is pouring a potential $3.5 billion into a partnership with circular RNA company Orna Therapeutics to develop and commercialize multiple oncology and infectious disease programs.
https://www.pharmalive.com/wp-content/uploads/2020/12/Merck-Strikes-1B-Deal-to-Leverage-Januxs-T-Cell-Engager-Program-Against-Cancer-BioSpace-12-18-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-16 10:42:362022-08-16 10:42:36Merck makes another big R&D investment with $3.5B Orna deal
